Quarterly and annual results disclosed under 8-K Item 2.02.
Zentalis Pharmaceuticals, Inc. reported financial results for the year ended December 31, 2025.
“On March 26, 2026, Zentalis Pharmaceuticals, Inc. (the “Company”) announced its financial results for the year ended December 31, 2025, and commented on certain business updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this "Current Report") and is incorporated herein by reference.”
MeiraGTx Holdings plc reported financial results for the year ended December 31, 2025.
“On March 26, 2026, the Company issued a press release announcing its financial results for the year ended December 31, 2025.”
Inhibikase Therapeutics, Inc. reported year ended December 31, 2025 results: net income $48.3 million, EPS $0.49 per share.
“Net loss for the year ended December 31, 2025, was $48.3 million, or $0.49 per share, compared to a net loss of $27.5 million, or $1.16 per share in the year ended December 31, 2024.”
MapLight Therapeutics, Inc. reported the full year 2025 results: net income $161.2 million.
“For the full year 2025, net loss was $161.2 million, as compared to $77.6 million for the full year 2024.”
MapLight Therapeutics, Inc. reported the fourth quarter of 2025 results: net income $79.5 million.
“Net loss was $79.5 million for the fourth quarter of 2025, as compared to $21.2 million for the prior year period.”
SpyGlass Pharma, Inc. reported financial results for fourth quarter and fiscal year ended December 31, 2025.
“On March 26, 2026, SpyGlass Pharma, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2025.”
Lucid Diagnostics Inc. reported fourth quarter and full year ended December 31, 2025 results: revenue $1.5 million, net income approximately $16.3 million or $(0.12) per common share, EPS $(0.12) per common share.
“--- Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results Processed 3,664 EsoGuard ® tests and recognized 4Q25 revenue of $1.5 million Expanded EsoGuard access with U.S. Department of Veterans Affairs contract award and strengthened clinical evidence with positive data from the largest reported real-world”
Gain Therapeutics, Inc. reported year ended December 31, 2025 results: net income Net loss for the year ended December 31, 2025, was $20.2 million, or $0.61 per share, basic and diluted, EPS $0.61 per share, basic and diluted.
“Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update BETHESDA, MD, March 26, 2026 -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the fourth quarter and year ended December 31, 2025, and provided a corporate update.”
Xos, Inc. reported the fourth quarter and full year ended December 31, 2025 results: revenue $5.2 million in revenue in the fourth quarter.
“operating loss of $14.6 million and a non-GAAP operating loss of $6.4 million in Q4 2024 — a 27.1% improvement in non-GAAP operating loss. • Xos delivered 34 units and generated $5.2 million in revenue in the fourth quarter, compared to 51 units and $11.5 million in Q4 2024 as the Company began shifting focus and allocating resources to powertrain production as”
Guerrilla RF, Inc. reported the year ended December 31, 2025 results: revenue $22.7 million, EPS $0.67.
“Full Year 2025 Highlights Management believes these full year 2025 results demonstrate a clear transition towards profitability, with substantial operating loss reduction, improved margins, and significantly lower cash burn. ● Revenue increased 13% to $22.7 million, reflecting continued product momentum. ● Gross profit grew 16% to $14.9 million, outpacing revenue as a result of changes in product price and mix. ● Gross profit margin expanded to 65.3%, up 160 basis points, demonstrating improving product mix and scale benefits. Significant Operating Leverage and Loss Reduction ● Operating loss improved by $4.1 million to $4.7 million, at 47% year over year reduction. ● Total operating expenses declined by $2.1 million, or 10%, driven by disciplined cost management. Dramatic Improvement in Cash Efficiency ● Cash used in operations reduced to $1.4 million, compared to $6.7 million in 2024, representing an approximately 79% improvement. ● Improvement driven by stronger margins, lower opera”
Guerrilla RF, Inc. reported the fourth quarter ended December 31, 2025 results: revenue $6.7 million.
“Fourth Quarter 2025 Highlights ● Revenue increased 53% year over year to $6.7 million, a new quarterly record ● Gross profit rose 68% year over year to $4.5 million. ● Gross profit margin increased to 66.4%, up 600 basis points year over year. ● Operating expenses declined 24% year over year to $4.4 million, reflecting the efficiency actions the Company executed during the year. ● Achieved operating income of approximately $55 thousand, a significant improvement compared to an operating loss of $3.1 million in the prior year quarter. ● Generated positive operating cash flow of $1.1 million, marking a significant financial milestone.”
P3 Health Partners Inc. reported financial results for the fourth quarter ended December 31, 2025.
“P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced its financial results for the fourth quarter and full year ended December 31, 2025, and provided 2026 guidance.”
P3 Health Partners Inc. reported financial results for the year ended December 31, 2025.
“On March 26, 2026, P3 Health Partners Inc. (the “Company”) announced its financial results for the year ended December 31, 2025.”
Dermata Therapeutics, Inc. reported financial results for year ended December 31, 2025.
“Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025”
Rani Therapeutics Holdings, Inc. reported fourth quarter and year ended December 31, 2025 results: revenue $1.5 million.
“to the Chugai agreement, to be sufficient to fund its operations into the fourth quarter of 2027. • Contract revenue for the three and twelve months ended December 31, 2025 were $1.5 million and $1.6 million, respectively. Of this, $1.5 million was attributed to a License and Collaboration Agreement and $0.1 million was attributed to evaluation services performed for”
Southland Holdings, Inc. reported for the quarter and year ended December 31, 2025 results: revenue Revenue of $104.0 million for the quarter ended December 31, 2025, net income Net loss attributable to stockholders of $216.4 million, or $(4.00) per share for the quarter ended December 31, 2025, EPS $(4.00).
“Revenue of $104.0 million for the quarter ended December 31, 2025, compared to $267.3 million for the quarter ended December 31, 2024.”
Worthington Steel, Inc. reported the three months ended February 28, 2026 (the third quarter of fiscal 2026) results: revenue $769.8 million, net income $10.4 million, EPS $0.20.
“financial results for the fiscal 2026 third quarter ended February 28, 2026. Third Quarter Highlights (all comparisons to the third quarter of fiscal 2025) : • Net sales of $769.8 million increased 12% compared to $687.4 million. • Operating income of $3.1 million compared to $18.3 million. • Net earnings attributable to controlling interest of $10.4 million”
Kyverna Therapeutics, Inc. reported financial results for fourth quarter and full year ended December 31, 2025.
“Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results”
Upstream Bio, Inc. reported financial results for the quarter and year ended December 31, 2025.
“On March 26, 2026, Upstream Bio, Inc. (the “Company”) announced its financial results and business highlights for the quarter and year ended December 31, 2025.”
Newsmax Inc. reported financial results for three months and full year ended December 31, 2025.
“On March 26, 2026, Newsmax Inc. (the "Company") issued a press release announcing its results of operations for the three months and full year ended December 31, 2025.”
Lumexa Imaging Holdings, Inc. updated its the quarter and year ended December 31, 2025 guidance (reaffirmed).
“On March 26, 2026, Lumexa Imaging Holdings, Inc. (the “Company”) issued a press release announcing certain preliminary financial information for the quarter and year ended December 31, 2025.”
COMMERCIAL METALS Co reported financial results for second quarter of fiscal year 2026.
“On March 26, 2026, CMC issued a press release announcing its financial results for the second quarter of fiscal year 2026. A copy of the press release is attached hereto as Exhibit 99.1.”
DIXIE GROUP INC reported fiscal year 2025 results: revenue $257,429,000, net income net loss of $7,615,000, EPS $0.52 per diluted share.
“For the fiscal year 2025, net sales for the Company were $257,429,000 or 2.9% below the net sales of $265,026,000 in the fiscal year 2024. The net loss from continuing operations on the year was $7,275,000 in 2025, or $0.50 per diluted share, compared to a net loss of $12,210,000, or $0.83 per diluted share, in 2024. The net loss on the year was $7,615,000, or $0.52 per diluted share, compared to a net loss of $13,000,000, or $0.88 per diluted share, in 2024.”
DIXIE GROUP INC reported the fourth quarter and the year ended December 27, 2025 results: revenue $63,487,000, net income net loss of $3,001,000.
“The Dixie Group, Inc. (OTCQB: DXYN) today reported financial results for the fourth quarter and the year ended December 27, 2025. In the fourth quarter of 2025, net sales were $63,487,000 or 1.4% below the net sales in the fourth quarter of 2024 at $64,338,000. The net loss for the fourth quarter of 2025 was $3,001,000. This compares to a net loss of $7,198,000 in the fourth quarter of 2024. For the fiscal year 2025, net sales for the Company were $257,429,000 or 2.9% below the net sales of $265,026,000 in the fiscal year 2024. The net loss from continuing operations on the year was $7,275,000 in 2025, or $0.50 per diluted share, compared to a net loss of $12,210,000, or $0.83 per diluted share, in 2024. The net loss on the year was $7,615,000, or $0.52 per diluted share, compared to a net loss of $13,000,000, or $0.88 per diluted share, in 2024.”
FULLER H B CO reported fiscal 2026 results: EPS $4.55 to $4.90. Guidance raised.
“As a result of our year-to-date performance and current macroeconomic conditions, we are updating our previously communicated financial guidance for the following items for fiscal 2026: ■ Net revenue for fiscal 2026 is now expected to be up mid-single digits; organic revenue is now expected to be up low-single digits and the impact from foreign exchange is now expected to be positive 1% to 2%; ■ Adjusted EBITDA for fiscal 2026 is now expected to be in the range of $645 million to $675 million; ■ Adjusted EPS (diluted) is now expected to be in the range of $4.55 to $4.90;”
FULLER H B CO reported the first quarter ended February 28, 2026 results: revenue $771 million, net income $21 million, EPS $0.38. Guidance raised.
“– H.B. Fuller Company (NYSE: FUL) today reported financial results for its first quarter that ended February 28, 2026. First Quarter 2026 Noteworthy Items: ■ Net revenue was $771 million; organic revenue was down 6.6% year-on-year; ■ Gross margin was 30.6%; adjusted gross margin of 31.3% increased 170 basis points year-on-year driven by restructuring savings from”
STIFEL FINANCIAL CORP reported preliminary financial results for February 28, 2026.
“Stifel Financial Corp. (NYSE: SF) today reported selected operating results for February 28, 2026, to provide timely information to investors on certain key performance metrics.”
NORTECH SYSTEMS INC reported the fourth quarter ended December 31, 2025 results: revenue $30.3 million, net income $897 thousand, EPS $0.32 per basic share.
“Nortech Systems Incorporated (Nasdaq: NSYS) (“Nortech” or the “Company”), a leading provider of engineering and manufacturing solutions for complex electromedical and electromechanical products serving the medical imaging, medical device, industrial, and aerospace & defense markets, reported financial results for the fourth quarter ended December 31, 2025. 2025 Q4 Highlights: ● Net sales of $30.3 million in Q4 2025 vs. $28.6 million in Q4 2024 ● Net income of $897 thousand, or $0.32 per basic share in Q4 2025 vs. $(1,478) thousand, or $(0.54) per basic share in Q4 2024”
REX AMERICAN RESOURCES Corp reported fourth quarter of fiscal 2025 (Q4 2025) results: revenue $158.0 million, net income $43.7 million, EPS $1.32.
“per share in Full Fiscal Year ‘25 § Reported gross profit of $28.9 million for fourth quarter and $93.7 million for Full Fiscal Year ‘25 § Reported net sales and revenue of $158.0 million for fourth quarter and $650.5 million for Full Fiscal Year ’25 § Reported consolidated ethanol sales volumes of 70.1 million gallons for fourth quarter and 290.0 million gallons”
REX AMERICAN RESOURCES Corp reported Full Fiscal Year 2025 results: revenue $650.5 million, net income $83.0 million, EPS $2.50.
“§ Reported gross profit of $28.9 million for fourth quarter and $93.7 million for Full Fiscal Year ‘25 § Reported net sales and revenue of $158.0 million for fourth quarter and $650.5 million for Full Fiscal Year ’25 § Reported consolidated ethanol sales volumes of 70.1 million gallons for fourth quarter and 290.0 million gallons for Full Fiscal Year ’25 Dayton, OH -”
OXFORD INDUSTRIES INC updated its the fourth quarter and fiscal year ended January 31, 2026 guidance (initiated).
“On March 26, 2026, Oxford Industries, Inc. issued a press release announcing, among other things, its financial results for the fourth quarter and fiscal year ended January 31, 2026.”
INTERLINK ELECTRONICS INC reported the fourth quarter ended December 31, 2025 results: revenue $2,853, net income $(574), EPS $(0.04).
“Results (Amounts in thousands except per share data and percentages) Three Months Ended December 31, Year Ended December 31, 2025 2024 $ ∆ % ∆ 2025 2024 $ ∆ % ∆ Revenue $ 2,853 $ 2,986 $ (133 ) (4.5 )% $ 11,890 $ 11,679 $ 211 1.8 % Gross profit $ 905 $ 1,183 $ (278 ) (23.5 )% $ 4,630 $ 4,846 $ (216 ) (4.5 )% Gross margin 31.7 % 39.6 % 38.9 % 41.5 %”
SYPRIS SOLUTIONS INC reported the fourth quarter and year ended December 31, 2025 results: revenue $30.3 million, net income net loss of $3.9 million, EPS $0.17 per share.
“The Company reported revenue of $30.3 million for the fourth quarter of 2025 compared to $33.4 million for the prior-year comparable period. Additionally, the Company reported a net loss of $3.9 million, or $0.17 per share, compared with net income of $0.1 million, or $0.01 per diluted share, for the prior-year period.”
SHOE CARNIVAL INC reported fiscal year ended January 31, 2026 results: revenue $1.135 billion, net income $52.3 million, EPS $1.90 per diluted share.
“fourth quarter EPS by approximately $0.08, primarily impacting selling, general and administrative expenses. Fiscal Year 2025 Operating Results Net sales for Fiscal 2025 were $1.135 billion, a decrease of 5.6 percent compared to Fiscal 2024, including a comparable store sales decline of 5.6 percent. The Shoe Carnival net sales decline of 7.7 percent was the primary”
SHOE CARNIVAL INC reported fourth quarter and fiscal year ended January 31, 2026 results: revenue $254.1 million, net income $9.1 million, EPS $0.33 per diluted share.
“to merchandise each banner according to the preferences of each store’s customer base.” Fourth Quarter 2025 Operating Results Net sales in the fourth quarter of Fiscal 2025 were $254.1 million, near the midpoint of the Company's guidance range, compared to $262.9 million in the fourth quarter of Fiscal 2024. Comparable store sales declined 3.5 percent. By banner: •”
Global Self Storage, Inc. reported the fourth quarter and full year ended December 31, 2025 results: revenue $3.2 million (Q4), net income $323,000 or $0.03 per diluted share (Q4), EPS $0.03 per diluted share (Q4).
“self-storage properties, reported results for the fourth quarter and full year ended December 31, 2025. All comparisons are to the same year-ago period unless otherwise noted. Q4 2025 Highlights • Total revenues decreased 0.9% to $3.2 million. • Net income increased to $323,000 or $0.03 per diluted share from $84,000 or $0.01 per diluted share. •”
EDAP TMS SA updated its the fourth quarter and full-year 2025 guidance (reaffirmed).
“On March 25, 2026, EDAP TMS S.A. issued a press release and will hold a conference call regarding its financial results for the quarter ended December 31, 2025.”
WINNEBAGO INDUSTRIES INC reported second quarter of Fiscal 2026 ended February 28, 2026 results: revenue $657.4 million, net income $4.8 million, EPS $0.17 per diluted share. Guidance reaffirmed.
“Winnebago Industries, Inc. (NYSE: WGO), a leading manufacturer of outdoor recreation products, today reported financial results for the Fiscal 2026 second quarter ended February 28, 2026. Second Quarter Fiscal 2026 Financial Summary • Net revenues of $657.4 million compared to $620.2 million in the second quarter of Fiscal 2025 • Gross profit of $85.6 million, representing 13.0% gross margin, compared to $83.1 million in the second quarter of Fiscal 2025 • Net income of $4.8 million, or $0.17 per diluted share; adjusted earnings per diluted share of $0.27 compared to adjusted earnings per diluted share of $0.19 in the second quarter of Fiscal 2025 • Adjusted EBITDA of $24.4 million, up 7.0% year-over-year”
Comstock Inc. reported financial results for fiscal year ended December 31, 2025.
“On March 24, 2026, Comstock Inc. announced its results of operations for the fiscal year ended December 31, 2025.”
Cytosorbents Corp reported financial results for the quarter and year ended December 31, 2025.
“On March 25, 2026, CytoSorbents Corporation issued a press release announcing its financial results for the quarter and year ended December 31, 2025.”
DYADIC INTERNATIONAL INC reported financial results for the year ended December 31, 2025.
“On March 25, 2026, Dyadic International, Inc. (“Dyadic”) issued a press release announcing its results for the year ended December 31, 2025.”
MARCHEX INC reported first quarter 2026 and second quarter 2026 and full year 2026 results: revenue in the first quarter of 2026 Marchex currently anticipates that revenue will be in the range of fourth quarter 2025 leve.
“Revenue in the first quarter of 2026 reflects the migration revenue dilution from the final platform switch over in December 2025, which impacted revenue run rates entering 2026. With this noted, in the first quarter of 2026 Marchex currently anticipates that revenue will be in the range of fourth quarter 2025 levels, and that Adjusted EBITDA will be $500,000 or more.”
MARCHEX INC reported fourth quarter and full year ended December 31, 2025 results: revenue GAAP revenue was $10.8 million for the fourth quarter of 2025, compared to $11.9 million for the fourth quarter of 2024., net income Net loss was $2.3 million for the fourth quarter of 2025 or $(0.05) per diluted share, compared to a net loss of $1.9 mi, EPS Net loss was $2.3 million for the fourth quarter of 2025 or $(0.05) per diluted share, compared to a net loss of $1.9 mi.
“Marchex Announces Fourth Quarter and Full Year 2025 Results and Archenia Transaction Update SEATTLE, WA – March 25, 2026 – Marchex, Inc. (NASDAQ: MCHX), which harnesses the power of AI and conversation intelligence to provide actionable insights derived from prescriptive vertical market data analytics, today announced its financial results for the fourth quarter and full year ended December 31, 2025. Q4 2025 and Full Year 2025 Financial Highlights • GAAP revenue was $10.8 million for the fourth quarter of 2025, compared to $11.9 million for the fourth quarter of 2024. GAAP revenue was $45.4 million for 2025, compared to $48.1 million for 2024. • Net loss was $2.3 million for the fourth quarter of 2025 or $(0.05) per diluted share, compared to a net loss of $1.9 million or $(0.04) per diluted share for the fourth quarter of 2024. Net loss was $5.2 million for 2025 or $(0.12) per diluted share, compared to a net loss of $4.9 million for 2024 or $(0.11) per diluted share.”
NOODLES & Co reported financial results for fourth quarter and fiscal year ended December 30, 2025.
“On March 25, 2026, Noodles & Company (the "Company") issued a press release disclosing earnings and other financial results for its fiscal quarter and fiscal year ended December 30, 2025”
Dolphin Entertainment, Inc. reported the fourth quarter ended December 31, 2025 results: revenue $15.6 million, net income Q4’25 Net Income of $1.0M vs. Net Loss of $2.0M in Q4 24. Guidance reaffirmed.
“and growth investments, we are now reaping the benefits. Full-year revenue grew approximately 10% to $56.7 million, with fourth quarter revenue up 27% year-over-year to $15.6 million. Full-year Adjusted EBITDA reached $2.9 million, up 209% from $0.9 million. Q4 was particularly strong, with Adjusted EBITDA of $1.7 million compared to Adjusted EBITDA loss of”
Dolphin Entertainment, Inc. reported the year ended December 31, 2025 results: revenue $56.7 million, net income Net loss for full year 2025 was $3.1 million, EPS $(0.27). Guidance reaffirmed.
“a turning point for Dolphin. After several years of strategic acquisitions and growth investments, we are now reaping the benefits. Full-year revenue grew approximately 10% to $56.7 million, with fourth quarter revenue up 27% year-over-year to $15.6 million. Full-year Adjusted EBITDA reached $2.9 million, up 209% from $0.9 million. Q4 was particularly strong, with”
KalVista Pharmaceuticals, Inc. reported the eight months ended December 31, 2025 results: revenue $49.1 million global net product revenue.
“KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update $49.1 million global net product revenue of EKTERLY ® (sebetralstat) for the eight months ended December 31, 2025”
PRECIGEN, INC. reported financial results for year ended December 31, 2025.
“Precigen, Inc., dated March 25, 2026, reporting its financial results for the year ended December 31, 2025.”
KIORA PHARMACEUTICALS INC reported the fourth quarter and full year ended December 31, 2025 results: net income The Company reported a net loss of $6.5 million in the fourth quarter of 2025, compared with a net loss of $4.2 million.
“Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials”
ProMIS Neurosciences Inc. reported the year ended December 31, 2025 results: net income $39.7 million.
“For the year ended December 31, 2025, the Company reported a net loss of $39.7 million”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.